Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. MU /
  3. YPH.MU

Astellas Pharma Inc (YPH MU) stock market data APIs

€10.005 0(0%) as of July 26, 2024
Price chart is built with Anychart

There is no Profile data available for YPH.MU.

Astellas Pharma Inc Financial Data Overview

10.005
10.005
-
10.005
10.005
-24.83-14.105
25 701 M
0
0
1.4099
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'YPH',
Type: 'Common Stock',
Name: 'Astellas Pharma Inc',
Exchange: 'MU',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Germany',
CountryISO: 'DE',
OpenFigi: NULL,
ISIN: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'March',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Other',
Industry: 'Other',
}

Astellas Pharma Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA 0
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Astellas Pharma Inc Earnings via APIs

  • Latest Release 2024-08-01
  • EPS/Forecast NaN

Get Astellas Pharma Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Astellas Pharma Inc latest news via APIs

Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer

-       If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union -       A decision on the EU marketin...

Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care for t...
Do you have any questions?
support@eodhistoricaldata.com